Related references
Note: Only part of the references are listed.Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity
Ekkehard Moessner et al.
BLOOD (2010)
Anti-CD20 monoclonal antibodies: historical and future perspectives
Sean H. Lim et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
Phase 1/2 study of fractionated 131I-rituximab in low-grade B-cell lymphoma: the effect of prior rituximab dosing and tumor burden on subsequent radioimmunotherapy
Tim M. Illidge et al.
BLOOD (2009)
Tumor burden influences exposure and response to rituximab: pharmacokinetic-pharmacodynamic modeling using a syngeneic bioluminescent murine model expressing human CD20
David Dayde et al.
BLOOD (2009)
The antileukemia activity of a human anti-CD40 antagonist antibody, HCD122, on human chronic lymphocytic leukemia cells
Mohammad Luqman et al.
BLOOD (2008)
Targeting Bcl-2 family proteins modulates the sensitivity of B-cell lymphoma to rituximab-induced apoptosis
Claudia Stolz et al.
BLOOD (2008)
Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activation
Stephen A. Beers et al.
BLOOD (2008)
Lymphoma depletion during CD20 immunotherapy in mice is mediated by macrophage FcγRI, FcγRIII, and FcγRIV
Veronique Minard-Colin et al.
BLOOD (2008)
Radiation therapy with tositumomab (B1) anti-CD20 monoclonal antibody initiates extracellular signal-regulated kinase/mitogen-activated protein kinase-dependent cell death that overcomes resistance to apoptosis
Andrey Ivanov et al.
CLINICAL CANCER RESEARCH (2008)
Induction of cytosolic calcium flux by CD20 is dependent upon B cell antigen receptor signaling
Claire A. Walshe et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study
Bertrand Coiffier et al.
BLOOD (2008)
Rituximab-CD20 complexes are shaved from Z138 mantle cell lymphoma cells in intravenous and subcutaneous SCID mouse models
Yongli Li et al.
JOURNAL OF IMMUNOLOGY (2007)
Mechanisms of killing by anti-CD20 monoclonal antibodies
Martin J. Glennie et al.
MOLECULAR IMMUNOLOGY (2007)
Depletion of B cells in murine lupus: Efficacy and resistance
Anupama Ahuja et al.
JOURNAL OF IMMUNOLOGY (2007)
Chemotherapy exposure increases leukemia cell stiffness
Wilbur A. Lam et al.
BLOOD (2007)
Antibodies, Fc receptors and cancer
Falk Nimmerjahn et al.
CURRENT OPINION IN IMMUNOLOGY (2007)
The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20
Jessica L. Teeling et al.
JOURNAL OF IMMUNOLOGY (2006)
The shaving reaction: Rituximab/CD20 complexes are removed from mantle cell lymphoma and chronic lymphocytic leukemia cells by THP-1 monocytes
PV Beum et al.
JOURNAL OF IMMUNOLOGY (2006)
The peritoneal cavity provides a protective niche for B1 and conventional B lymphocytes during anti-CD20 immunotherapy in mice
Y Hamaguchi et al.
JOURNAL OF IMMUNOLOGY (2005)
Rituxan (anti-CD20 antibody)-induced translocation of CD20 into lipid rafts is crucial for calcium influx and apoptosis
E Janas et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2005)
Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy
Q Gong et al.
JOURNAL OF IMMUNOLOGY (2005)
Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents
MS Cragg et al.
BLOOD (2004)
VavP-Bcl2 transgenic mice develop follicular lymphoma preceded by germinal center hyperplasia
A Egle et al.
BLOOD (2004)
FcγRIIIa and Fc-γRIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia
SS Farag et al.
BLOOD (2004)
Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas
JL Teeling et al.
BLOOD (2004)
Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin
CD Austin et al.
MOLECULAR BIOLOGY OF THE CELL (2004)
The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy
JJ Uchida et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2004)
Apparent modulation of CD20 by rituximab: an alternative explanation
MS Cragg et al.
BLOOD (2004)
Transient down-modulation of CD20 by rituximab in patients with chronic lymphocytic leukemia
I Jilani et al.
BLOOD (2003)
Rituximab in B-cell chronic lymphocytic leukemia
TS Lin et al.
SEMINARS IN ONCOLOGY (2003)
Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance
T Manshouri et al.
BLOOD (2003)
Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma
WK Weng et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Alanine-170 and proline-172 are critical determinants for extracellular CD20 epitopes; heterogeneity in the fine specificity of CD20 monoclonal antibodies is defined by additional requirements imposed by both amino acid sequence and quaternary structure
MJ Polyak et al.
BLOOD (2002)
Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene
G Cartron et al.
BLOOD (2002)
Emerging information on the use of rituximab in chronic lymphocytic leukemia
MJ Keating et al.
SEMINARS IN ONCOLOGY (2002)
Higher levels of surface CD20 expression on circulating lymphocytes compared with bone marrow and lymph nodes in B-cell chronic lymphocytic leukemia
YO Huh et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2001)
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
RA Clynes et al.
NATURE MEDICINE (2000)
Share Paper
